Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
1580
Trial Sponsor
Clinical Trial Start Date
September 18, 2024
0Primary Completion Date
September 30, 2027
0Study Completion Date
October 31, 2027
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma0
Last Updated
September 19, 2024
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
Pembrolizumab0
ALN-BCAT0
Study summary
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
